Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update - PubMed
2 months ago
- #Emicizumab
- #Bispecific antibodies
- #Hemophilia A
- Bispecific antibodies, like emicizumab, mimic Factor VIII (FVIII) activity to treat hemophilia A, reducing bleeding rates.
- Emicizumab is currently the only approved FVIII-mimetic bispecific antibody, improving musculoskeletal health and quality of life in patients with or without inhibitors.
- New FVIII-mimetic bispecific antibodies, such as Mim8 and NXT007, are under clinical trials, showing promise for easier dosing and good safety profiles.
- These treatments represent a shift from traditional FVIII replacement therapies, offering long-acting, subcutaneous options for prophylaxis.
- Challenges include monitoring activity, managing breakthrough bleeds, and understanding FVIII's non-hemostatic roles in the body.